One Health Biosensing
Develops affordable next-generation CGM and biosensors for human, animal, and environmental health diagnostics.
Website: https://onehealthbiosensing.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | One Health Biosensing |
| Tagline | Develops affordable next-generation CGM and biosensors for human, animal, and environmental health diagnostics |
| Headquarters | New York, United States |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Repeat Founder |
| Funding Label | Undisclosed (Wefunder community round) |
Links
PUBLIC
- Website: https://onehealthbiosensing.com/
- LinkedIn: https://www.linkedin.com/company/one-health-biosensing
- Wefunder: https://wefunder.com/onehealthbiosensing/
- Crunchbase: https://www.crunchbase.com/organization/one-health-biosensing
Executive Summary
PUBLIC
One Health Biosensing is an early-stage New York healthtech company building what it describes as next-generation continuous glucose monitoring (CGM) hardware and a broader biosensor platform intended to span human, animal, and environmental diagnostics [Crunchbase, 2024]. The company was incorporated in February 2024 by Jeffrey Dachis, who previously founded and led the diabetes management company One Drop and, earlier in his career, co-founded the digital agency Razorfish [Kingscrowd, 2024] [Crunchbase, 2024]. The pitch on its website is unusually direct for a hardware company: technology "built and priced to be accessible and affordable on day one," framed explicitly around closing health disparities in chronic disease monitoring [One Health Biosensing website, 2024]. Differentiation, per Kingscrowd's profile of the offering, rests on a portfolio described as more than 50 issued patents covering biomonitoring and glucose forecasting, including European Patent EP3977480A1 originally assigned to Informed Data Systems Inc., the legal entity behind One Drop [Kingscrowd, 2024] [Google Patents, 2026]. The company is currently raising a Regulation Crowdfunding round on Wefunder with a stated minimum target of $50,000, an unusual capitalization path for a CGM hardware program but consistent with a pre-institutional stage [Kingscrowd, 2024]. Over the next 12 to 18 months the questions worth tracking are whether the company converts the patent portfolio into a regulatory pathway (FDA 510(k) or De Novo for a CGM is a multi-year process), whether it discloses an institutional lead investor, and whether its veterinary or environmental sensor lines materialize into shipping products rather than positioning. The team's prior exit history is a meaningful asset, but the public record does not yet show shipping product, clinical data, or named institutional backers, which is why this report treats the bet as credible founder, unproven execution.
Data Accuracy: GREEN -- Confirmed by Crunchbase, Kingscrowd, Wefunder, and Google Patents.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech (CGM and biosensing) |
| Technology Type | Biotech / Life Sciences |
| Geography | North America (New York HQ) |
| Growth Profile | Venture Scale |
| Founding Team | Repeat Founder |
| Funding | Undisclosed pre-seed; active Wefunder community round |
Company Overview
PUBLIC
One Health Biosensing was founded in February 2024 in New York by Jeffrey Dachis, according to Kingscrowd's profile of the company's Wefunder campaign [Kingscrowd, 2024]. PitchBook independently lists 2024 as the founding year [PitchBook, 2024]. Crunchbase identifies Dachis as Founder and CEO and notes his prior role as Founder, Chairman, and CEO of One Drop, the diabetes management company that built a coaching app, a Bluetooth glucose meter, and a digital health subscription service [Crunchbase, 2024].
The company's positioning, drawn directly from its homepage, is that "health disparity is real and we want to be part of the solution" and that its technology is "built and priced to be accessible and affordable on day one" [One Health Biosensing website, 2024]. That framing is consequential: most CGM products on the U.S. market today are priced as prescription-grade medical devices, and a pre-seed entrant explicitly targeting affordability is taking a position on cost structure rather than on incremental sensor accuracy. Crunchbase adds that the scope extends beyond human diabetes care into biosensors for animal and environmental health diagnostics, which would, if executed, place the company in three regulated markets simultaneously [Crunchbase, 2024].
Key verifiable milestones to date are narrow: incorporation in February 2024 [Kingscrowd, 2024], launch of a Wefunder community round with a $50,000 minimum target [Kingscrowd, 2024], and a campaign update reporting that the round had exceeded its initial goal and was being extended for additional investor participation [Wefunder, 2024]. No product launch, FDA submission, clinical study, or institutional financing has been publicly disclosed in the cited sources.
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and Kingscrowd.
Product and Technology
MIXED
The public product description centers on a continuous glucose monitor positioned on cost and accessibility rather than on a novel biosensing modality. The company's website describes "next generation" CGM technology built to be accessible and affordable [One Health Biosensing website, 2024]. The Wefunder campaign characterizes the offering more specifically as an "AI-enabled, ultra low cost CGM" [Wefunder, 2024], language that is investor-pitch material rather than product specification and should be read as forward-looking. Beyond CGM, Crunchbase summarizes the company as developing "biosensors for diagnostics across human, animal, and environmental health," suggesting a platform strategy in which a common sensing stack is adapted to multiple end markets [Crunchbase, 2024].
The most concrete technology asset disclosed is the patent estate. Kingscrowd reports more than 50 issued patents associated with the company [Kingscrowd, 2024]. One specific filing is independently verifiable: European Patent EP3977480A1, covering "systems for biomonitoring and blood glucose forecasting," was originally assigned to Informed Data Systems Inc doing business as One Drop, the company Dachis previously led [Google Patents, 2026]. The chain of custody from One Drop's IP to One Health Biosensing is not detailed in the public record, but the existence of a granted European patent on glucose forecasting tied to the founder's prior company is materially more credible than a typical pre-seed IP claim.
No information is publicly available on the sensor chemistry, transmitter design, software architecture, mobile app, regulatory filings, or manufacturing arrangements. There are no open job postings on careers pages or major ATS hosts, so even tech-stack inference from hiring is not possible at this stage. Investors evaluating the product should request the patent schedule, any preclinical or analytical performance data, and the regulatory roadmap directly from the company.
Data Accuracy: YELLOW -- Patent EP3977480A1 confirmed via Google Patents; broader product and patent-count claims rest on company-supplied materials.
Market Research and Opportunity
PUBLIC
CGM has moved from a niche endocrinology tool to a mass-market category, and the question now is whether a low-cost entrant can carve a wedge under the incumbents. Continuous glucose monitoring as a category is dominated globally by Dexcom, Abbott (Freestyle Libre), and Medtronic, with Abbott's Libre franchise widely reported as the volume leader. The category was meaningfully reshaped in 2024 when both Dexcom (Stelo) and Abbott (Lingo and Libre Rio) launched over-the-counter CGM products in the United States targeted at non-diabetic and pre-diabetic users, broadening the addressable population well beyond the roughly 8.4 million insulin-using Americans who have historically been the prescription CGM base. The cited research set for this report does not contain a third-party TAM figure for CGM that is independently named and dated, so this report does not publish one; investors should rely on their own subscription data (Grand View, IQVIA, Decision Resources) for sizing.
Three demand drivers are visible in the broader public record and are relevant to One Health Biosensing's positioning. First, the OTC pivot in 2024 has structurally expanded who can buy a CGM without a prescription, which is the category most exposed to price competition. Second, GLP-1 adoption (Wegovy, Zepbound) has created a large new cohort of metabolically engaged consumers who are candidates for glucose tracking even without a diabetes diagnosis. Third, payer pressure on per-sensor pricing in Europe and in U.S. Medicare reimbursement creates a real opening for a lower-cost device, which is the lane the company has explicitly chosen [One Health Biosensing website, 2024].
Adjacent and substitute markets matter for the platform thesis. The veterinary diagnostics market is served today primarily by point-of-care chemistry and immunoassay analyzers from IDEXX, Zoetis, and Heska, with continuous biosensing largely absent at scale; an affordable continuous sensor would be a category creation play rather than a share-take. Environmental biosensing, the third leg of the company's stated scope [Crunchbase, 2024], is more fragmented and largely sold into industrial water, agriculture, and public-health monitoring channels with very different procurement cycles than human medical devices. The platform breadth is intellectually coherent (one sensing stack, three end markets) but each end market has its own regulatory regime, channel, and sales cycle.
Regulatory and macro forces cut both ways. A U.S. CGM requires either 510(k) clearance against a predicate or De Novo classification, both of which are multi-quarter to multi-year processes with meaningful clinical data requirements; the OTC pathway, while now established, still requires that clearance. On the macro side, the inflation in medical-device input costs that pressured 2022 to 2023 margins has eased, and contract-manufacturing capacity in Southeast Asia for wearable sensors is more available than it was during the post-COVID supply crunch, which is helpful for a cost-led entrant.
| Cited claim | Value | Source |
|---|---|---|
| Issued patents associated with company | More than 50 | [Kingscrowd, 2024] |
| Wefunder round minimum target | $50,000 | [Kingscrowd, 2024] |
| Founding year | 2024 | [PitchBook, 2024] |
The table above is the full set of company-specific quantitative claims that are publicly cited; sizing of the CGM market itself is not represented in the captured sources and is therefore omitted rather than estimated.
Data Accuracy: YELLOW -- Company-specific figures confirmed by Kingscrowd and PitchBook; market sizing context is contextual rather than from a single named report in the captured set.
Competitive Landscape
MIXED
One Health Biosensing is positioning under, not against, the established CGM franchises, betting that a lower price point opens a population the incumbents have not yet served at scale. The captured sources do not name specific competitors for One Health Biosensing, so the comparison table is omitted and the analysis runs as prose. Investors should treat the competitor names below as analyst-identified context, drawn from the public CGM category rather than from the structured fact set.
The segment map has three layers. The incumbents are Abbott (Freestyle Libre 3 Plus, Lingo, Libre Rio), Dexcom (G7, Stelo), and Medtronic (Guardian 4, Simplera), all of which sell FDA-cleared sensors at scale and have established payer contracts and pharmacy distribution. The challengers include Senseonics (the implantable Eversense, partnered with Ascensia) and a set of international players such as Sibionics and GlucoMen Day that have shipped CE-marked sensors but have limited U.S. presence. The adjacent substitutes are non-invasive optical and RF approaches (Know Labs, Rockley Photonics, various university spinouts) which have promised wrist-based glucose sensing for years without a cleared consumer product. One Health Biosensing has not yet disclosed which of these layers it most directly competes with, but the "ultra low cost" framing [Wefunder, 2024] suggests it is targeting the disposable-sensor architecture pioneered by Abbott rather than the implantable or optical approaches.
The defensible edge today, if it exists, is twofold and partially perishable. The patent estate, anchored by EP3977480A1 on glucose forecasting [Google Patents, 2026], is a real asset but forecasting algorithms are an area where the incumbents (especially Dexcom with its Stelo coaching layer and Abbott with Lingo) are themselves investing heavily; freedom-to-operate is more valuable than blocking power here. The founder's prior experience building One Drop into a venture-backed diabetes platform with payer contracts is genuinely rare in pre-seed hardware [Crunchbase, 2024]; that operating knowledge of the chronic-care purchaser is harder to replicate than the IP itself.
The company is most exposed on three axes. First, capital intensity: bringing a CGM through 510(k), pilot manufacturing, and launch typically requires tens of millions of dollars, and a Wefunder round with a $50,000 minimum target [Kingscrowd, 2024] is a starter step rather than a financing strategy. Second, channel: Abbott and Dexcom own retail pharmacy and DME distribution in a way that a new entrant will need years and a partner to replicate. Third, brand trust in a regulated category: clinicians and patients defaulting to a lower-priced unknown sensor is not automatic and will require clinical accuracy data (MARD figures benchmarked against YSI) that the company has not yet published. The most plausible 18-month scenario is that One Health Biosensing closes an institutional seed led by a healthtech-native fund, files for 510(k) on a first-generation sensor, and either signs a distribution partnership with a digital-health platform or remains a pre-clearance development-stage company. Winner if the company secures a strategic partner (for example, a GLP-1 distribution channel, a value-based primary-care network, or an international generics player) that wants a private-label sensor; loser if it spends 2025 to 2026 raising small tranches on Wefunder without a regulatory submission, in which case the OTC window will have been captured by Stelo and Lingo.
Opportunity
PUBLIC
If One Health Biosensing executes, the prize is a generational re-pricing of continuous biosensing, beginning with glucose and extending into adjacent species and matrices.
The headline opportunity is that One Health Biosensing becomes the low-cost reference architecture for continuous glucose monitoring globally, with the same sensing stack repurposed for veterinary chronic-disease monitoring and selected environmental applications. The reason this outcome is reachable rather than aspirational rests on three pieces of cited evidence. The founder has previously built and exited a diabetes-care company, One Drop, and is publicly identified as its founder, chairman, and CEO [Crunchbase, 2024], which is the single most relevant prior role for this category. The technology base is anchored by a granted European patent on biomonitoring and glucose forecasting [Google Patents, 2026], not just a provisional filing. And the company's stated thesis ("built and priced to be accessible and affordable on day one") [One Health Biosensing website, 2024] aligns with where the CGM category is actually moving in 2024 to 2025 with the launch of OTC sensors. None of this guarantees clearance or commercial success, but it establishes that the bet is coherent.
Two or three growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| OTC value brand | Company clears a 510(k) OTC CGM and sells direct-to-consumer at a price meaningfully below Stelo and Lingo | A clinical study demonstrating MARD competitive with cleared OTC devices, plus a contract-manufacturing partner | Founder previously built D2C diabetes brand at One Drop [Crunchbase, 2024]; OTC pathway is now established |
| Private-label platform | Company licenses or co-manufactures sensors for a GLP-1 program, payer, or international distributor | A signed supply agreement with a metabolic-health platform or generics player | Patent estate of 50+ issued patents [Kingscrowd, 2024] supports a licensable IP position |
| One Health platform | CGM funds expansion into veterinary continuous monitoring and environmental biosensing using the same sensor stack | A second product line clearance (USDA for animal, EPA-relevant for environmental) | Crunchbase describes the scope as spanning human, animal, and environmental diagnostics [Crunchbase, 2024] |
What compounding looks like. The flywheel in CGM is well understood from the incumbents' trajectories: each shipped sensor generates continuous data that improves the forecasting algorithm, which improves clinical claims and user retention, which lowers customer acquisition cost on the next cohort, which funds the next sensor generation. For a low-cost entrant, the additional compounding lever is unit-economics improvement: every doubling of cumulative sensor volume in disposable medical electronics has historically driven meaningful per-unit cost reduction, and a company that starts with a price-led positioning captures more of that curve than a premium-priced incumbent can. None of this flywheel is yet observable at One Health Biosensing in the public record; it is a description of how the bet would compound if the first product ships.
The size of the win. A credible public comparable is Dexcom, which trades as a multi-tens-of-billions market-capitalization company on a single-product CGM franchise, and Abbott's diabetes-care segment, which on disclosed segment revenue is one of the largest single medical-device franchises in the world. Senseonics, as a challenger comparable with a cleared but small-volume product, trades at a much smaller capitalization that reflects unproven scale economics. A reasonable scenario framing (scenario, not a forecast) is that One Health Biosensing in the OTC value-brand path could plausibly reach the revenue scale of a successful single-product medical-device challenger within five to seven years of clearance, with the platform path (veterinary plus environmental) representing optional upside that the public record does not yet support quantitatively. Investors should size the bet on the CGM opportunity alone and treat the broader "one health" framing as call-option value.
Data Accuracy: YELLOW -- Scenarios are constructed from cited founder background, patent evidence, and category context; no revenue, pipeline, or clearance milestones are yet publicly disclosed.
Sources
PUBLIC
[One Health Biosensing website, 2024] One Health Biosensing - Next generation CGM | https://onehealthbiosensing.com/
[PitchBook, 2024] One Health Biosensing 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/653548-33
[Kingscrowd, 2024] One Health Biosensing on Wefunder 2024 | https://kingscrowd.com/one-health-biosensing-on-wefunder-2024/
[Wefunder, 2024] One Health Biosensing: Over $5B in exits from team creating Razorfish, One Drop, Big Foot, Welldoc | https://wefunder.com/onehealthbiosensing/
[Wefunder, 2024] 9 days left - to invest in the future of CGM | https://wefunder.com/updates/181648-9-days-left-to-invest-in-the-future-of-cgm
[Crunchbase, 2024] One Health Biosensing - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/one-health-biosensing
[Crunchbase, 2024] Jeffrey Dachis - Founder & CEO @ One Health Biosensing | https://www.crunchbase.com/person/jeff-dachis
[Google Patents, 2026] EP3977480A1 - Systems for biomonitoring and blood glucose forecasting | https://patents.google.com/patent/EP3977480A1
[TechCrunch, 2013] Dachis Group, The Social Analytics Startup Led By Razorfish Co-Founder Jeff Dachis, Raises $7.5M More | https://techcrunch.com/2013/03/20/dachis-group-raises-7-5m-to-expand-its-big-data-social-analytics-platform/
[TechCrunch, 2010] Dachis Continues To Shop For Facebook Preferred Developers, Buys Archrival | https://techcrunch.com/2010/11/17/dachis-group-archrival/
[LinkedIn] One Health Biosensing company page | https://www.linkedin.com/company/one-health-biosensing
Articles about One Health Biosensing
- One Health Biosensing Wants a Glucose Sensor on Every Wrist That Cannot Afford One — Repeat founder Jeffrey Dachis is back with a pre-seed bet on a low-cost CGM, leaning on a 50-patent portfolio carried over from One Drop.